Introduction
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by the reciprocal translocation between chromosomes 9 and 22, resulting in the formation of a constitutively active tyrosine kinase, BCR-ABL. 1, 2 The resultant BCR-ABL oncoprotein is essential for chronic myeloid leukemia pathogenesis, 3 and mediates an increase in cell proliferation, a suppression of apoptosis, altered cell adhesion and genetic instability. [4] [5] [6] Imatinib mesylate (Novartis Pharmaceuticals™) competitively binds to the ATP-binding domain of BCR-ABL, 7 rendering it inactive and preventing downstream signaling. 8 As frontline therapy, imatinib results in excellent cytogenetic and molecular responses for the majority of chronic phase chronic myeloid leukemia (CP-CML) patients. 9 However, approximately 25% to 35% of patients display primary resistance or sub-optimal response to imatinib. 10 Therefore, identifying prognostic indicators of poor response to imatinib may enable tailored therapy for patients at risk. 11, 12 The organic cation transporter 1 (OCT-1, also known as SLC22A1) is the major active influx transporter for imatinib in chronic myeloid leukemia cells. 13, 14 A number of studies have found a relationship between OCT-1 mRNA expression and response to imatinib treatment; [15] [16] [17] however, this has not been confirmed in other studies. 18, 19 We have previously demonstrated that the functional activity of OCT-1 (OCT-1 activity) measured in mononuclear cells (MNC) from CP-CML patients at diagnosis is associated with their molecular response to imatinib treatment at both 24 months 20 and at five years. 19 Furthermore, we have established that OCT-1 activity is a strong predictor of event-free and transformation-free survival following five years of imatinib treatment. 19 It has recently been suggested that OCT-1 mRNA expression is increased in polymorphonuclear cells compared to mononuclear cells 21, 22 and that BCR-ABL may have an inhibitory effect on OCT-1 expression. 21 Given the strong predictive value of OCT-1 activity, the present study was aimed at identifying factors which may influence patient variation in OCT-1 activity. Specifically, the effects of cell lineage, cell maturity and BCR-ABL expression on OCT-1 activity were assessed.
Design and Methods

Patient samples
Peripheral Blood (PB) was obtained from CP-CML patients at diagnosis and once they had entered complete cytogenetic remission. Normal peripheral blood was obtained from healthy donors. All samples were collected with informed consent in accordance with the Institutional Ethics approved protocols and with reference to the Declaration of Helsinki.
Cell isolation
Mononuclear cells were isolated from peripheral blood by Ficoll density gradient centrifugation according to the manufacturer's instructions (Lymphoprep; Axis Shield, Oslo, Norway). For chronic myeloid leukemia diagnosis samples: mononuclear cells were enriched for monocytes using a Percoll continuous gradient (GE Healthcare, Uppsala, Sweden) and pure monocytes were then isolated using CD14 microbeads according to the manufacturer's instructions by magnetic-activated cell sorting (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany). Pure neutrophils and lymphocytes were also isolated from the mononuclear cell compartment using CD16 and CD3 MACS microbeads, respectively. For chronic myeloid leukemia remission samples and normal donors, monocytes and lymphocytes were enriched directly from mononuclear cells using CD14 and CD3 MACS microbeads, respectively. Granulocytes were obtained from the red blood cell layer of the Ficoll and were washed twice in red blood cell lysis buffer. Pure neutrophils were then isolated using CD16 MACS microbeads (see Online Supplementary Figure S1 for the entire cell lineage enrichment workflow). The purity of all MACS-purified populations was assessed using immunophenotyping and morphology (see Online Supplementary Figure S2 for purity assessment). 
Immunophenotyping
Drugs and kinase inhibitors
Imatinib mesylate (STI571) and [ 14 C]-imatinib, were kindly provided by Novartis Pharmaceuticals (Basel, Switzerland). Stock solutions of imatinib were prepared at concentrations of 1 and 10 mM in distilled water, sterile filtered and stored at -70°C. The potent OCT-1 inhibitor prazosin (Sigma-Aldrich, Steinheim, Germany) was used at 100μM in the intracellular uptake and retention (IUR) assay.
OCT-1 activity
OCT-1 activity was calculated from the IUR assay as described previously. 20 In brief, 2¥10 5 cells were incubated in the presence or absence of 2μM [ 14 C]-imatinib ± prazosin for 2 h at 37°C. Following this time, tubes were centrifuged to separate the cells from the supernatant and these were added to OptiPlates containing Microscint 20 scintillation fluid (both from PerkinElmer, Boston, MA, USA). Imatinib incorporation was determined using a Top Count Microplate b-Scintillation Counter (PerkinElmer). Imatinib uptake was calculated as ng of imatinib per 200,000 cells. The OCT-1 activity was expressed as the difference between the intracellular uptake and retention in the absence and presence of prazosin, as described earlier. 20 Where intracellular uptake and retention values in the presence of prazosin were equal or higher than the values in the absence of prazosin, these patients were scored as having negligible (0 ng/200,000 cells) OCT-1 activity.
mRNA expression of OCT-1
OCT-1 mRNA expression levels were determined as previously described. 23 Briefly, total RNA was extracted from 1¥10 6 -1¥10 7 cells using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA).
Complementary DNA was synthesized using random hexamers (GeneWorks Pty. Ltd, Hindmarsh, SA, Australia) and Superscript II Reverse Transcriptase (Invitrogen). OCT-1 and BCR were amplified using PCR primer sequences as previously reported. 23 Quantitative PCR (qPCR) was performed on a RotorGene 3000 real-time PCR thermal cycler (Qiagen, San Francisco, CA, USA) using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). OCT-1 mRNA expression was calculated as a percentage relative to BCR expression.
Cell culture
The promyelocytic HL60 cell line was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in RPMI-1640 media (Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum (JRH Biosciences, Lenexa, KS, USA), penicillin and streptomycin and L-glutamine at 37°C in a 5% CO2-humidified incubator.
Viral vector construction and transduction of cell lines
The pHIV-1SDm-based lentiviral vector and four accessory plasmids were used for Tat-dependent lentiviral vector production. 24 The SV40 promoter was exchanged for a CMV promoter and the woodchuck post-transcriptional regulatory element was added to generate pHIV-1SDmCMV.wpre. A control vector (CV) containing enhanced green fluorescent protein (eGFP) was generated by cloning in a BamHI/NotI Klenow-blunted fragment from peGFP-1 (BD Biosciences). The 6.1 kb BCR-ABL fusion gene cDNA representing the p210 variant was PCR-amplified from pSIN-p210 25 and fused to eGFP using the porcine teschovirus-1 2A peptide sequence (P2A) represented as the amino acids (SGSGAT-NFSLLKQAGDVEENPGP). This system allows stoichiometric expression of separate eGFP and BCR-ABL proteins resulting from a ribosomal skipping mechanism. 26 Lentiviral particles comprised of either control vector or wild-type BCR-ABL were generated as previously described. 27 Approximately 2¥10 5 HL60 cells were suspended in 500 μL of culture media in a 5 mL FACS tube. Polybrene (8 μg/mL) and concentrated viral particles (10 μL of control vector or 50 μL of BCRABL vector) were added to the cells and centrifuged at 1,500 rpm for three hours. 
Differentiation assays
Differentiation of the HL60 cell line into granulocytes was induced by adding 1.25% (v/v) DMSO (Dimethyl sulfoxide, Merck, Darmstadt, Germany) for seven days. 29, 30 Cell differentiation was monitored by cell growth, cell cycle status and antigen CD11b expression. 31 Furthermore, cytospin preparations were stained with Wright's stain for morphological assessment.
Cell cycle analysis
Following induction of differentiation, 5¥10 5 HL60 cells were washed once in phosphate-buffered saline (PBS, Sigma-Aldrich) and fixed in 100% ethanol at 4°C for a minimum of 24 h. Cells were then washed in PBS and incubated at 37°C for 40 minutes in a 1 mL PBS solution containing propidium iodide (40 μg/mL, Sigma-Aldrich), RNase A (100 μg/mL, Qiagen, Doncaster, Australia) and Triton X-100 (0.1% (v/v), Sigma-Aldrich). Cells were analyzed by flow cytometry (Beckman Coulter).
Statistics
All statistics were performed using SigmaStat 3.0 software (SPSS Inc., Chicago, IL, USA). The Mann-Whitney Rank Sum or the Student's t-test were used to determine differences between experimental groups as appropriate. Column graphs show mean plus the standard error of the mean (SEM). Data in tables show mean plus the standard deviation (SD).
Results
MNC OCT-1 activity and cell populations vary between CML diagnosis patients, remission patients and normal donors
Previous studies have shown that OCT-1 activity in mononuclear cells recovered from chronic myeloid leukemia patients at diagnosis is highly variable and that response to imatininb treatment is closely linked to OCT-1 activity. 19 To determine if this variation was a feature of chronic myeloid leukemia or was patient-specific, mononuclear cells were isolated from 16 chronic myeloid leukemia patients at diagnosis; 7 of these patients who had entered complete cytogenetic remission (CCR) following imatinib treatment, and 10 normal individuals. The OCT-1 activity in mononuclear cells recovered from chronic myeloid leukemia patients in complete cytogenetic remission was lower than that observed in mononuclear cells from chronic myeloid leukemia patients at diagnosis and was lowest in mononuclear cells from normal healthy individuals (average: CML diagnosis 12.8; CML remission 6.2; normal 3.4 ng/200,000 cells; Figure 1A ). To assess whether the low MNC OCT-1 activity in normal healthy volunteers was due to lineage differences in the mononu- Figure 1B) . Of interest, only 27% of the cells were positive for both CD15 and CD16 (mature neutrophil makers) indicating the presence of immature myelocytes and metamyelocytes. In contrast, the major populations present within remission chronic myeloid leukemia and normal mononuclear cells were found to be lymphoid in nature (average of 21% and 50% CD3 + lymphocytes, respectively). Morphological analysis confirmed these findings. These data suggest that the intrinsic differences between myeloid and lymphoid cells may account for the differences in imatinib uptake and hence OCT-1 activity in the mononuclear cell compartment of the various sample types.
OCT-1 activity is highest in the neutrophil population and is not influenced by BCR-ABL
The intrinsic OCT-1 activity of lineage marker-defined cell populations was examined following the isolation of populations enriched for CD15 + 
16
+ neutrophils, CD14 + monocytes or CD3 + lymphocytes from CML patients and normal donors (Online Supplementary Figures S1 and S2) . After examining samples from CML diagnosis, CML remission, and normal individuals, neutrophils were found to express the highest OCT-1 activity (means 9.1, 19.1, and 13.5 ng/200,000 cells, respectively), monocytes exhibited intermediate OCT-1 activity (means 5.8, 5.2, and 9.0 ng/200,000 cells, respectively), while lymphocytes exhibited the lowest OCT-1 activity (means 2.8, 1.5, and 2.0 ng/200,000 cells, respectively; Figure 2) . Furthermore, in all groups, OCT-1 activity in neutrophils was significantly higher than lymphocytes (P<0.001 for CML diagnosis, P=0.012 for CML remission, and P<0.001 for normal individuals). These data suggest that high MNC OCT-1 activity in chronic myeloid leukemia patients at diagnosis may be due to the predominance of granulocytes in the mononuclear cell population. Furthermore, the low mononuclear cell OCT-1 activity in CML remission and normal individuals may reflect the presence of greater numbers of lymphocytes. Consistent with this notion, there was no significant difference in neutrophil OCT-1 activity in samples collected from CML diagnosis, CML remission and normal individuals. This finding was also consistent in monocytes and lymphocytes, suggesting that BCR-ABL expression, absent or low in remission and absent in normal individuals, is unlikely to be affecting OCT-1 activity.
MNC OCT-1 activity is related to neutrophil OCT-1 activity
The relationship between MNC OCT-1 activity and OCT-1 activity in neutrophils, monocytes and lymphocytes was examined (Figure 3) . A significant correlation between MNC OCT-1 activity and neutrophil OCT-1 activity was observed in chronic myeloid leukemia
J.R. Engler et al.
216
haematologica | 2011; 96(2) Figure 2 . OCT-1 activity in neutrophils, monocytes and lymphocytes isolated from the study cohort. Data from CML patients at diagnosis, CML patients in CCR and normal individuals is shown, OCT-1 activity is expressed as ng/200,000 cells. Columns represent the mean + SEM. The P value demonstrates a significant difference in OCT-1 activity between neutrophils and lymphocytes for all groups. Figure 3A and B). A significant correlation was also found between CML diagnosis mononuclear cell OCT-1 activity and monocyte OCT-1 activity (r=0.617, P=0.014; Figure 3C ). No relationship was observed between the OCT-1 activity in lymphocytes and mononuclear cells ( Figure 3E and F).
OCT-1 mRNA expression is highest in the neutrophil population
In order to determine whether messenger RNA levels may contribute to the variation in OCT-1 activity observed in the different cell lineages, qPCR was employed. As demonstrated in Table 1 , the highest level of OCT-1 mRNA expression was seen in the neutrophil population, while the lowest expression was observed in the lymphocytes (P=0.026 for CML diagnosis, P=0.016 for CML remission and P<0.001 for normal donors). No difference in neutrophil OCT-1 mRNA expression was observed in samples recovered from CML diagnosis patients, CML remission patients and normal healthy individuals. However, monocytes and lymphocytes from CML diagnosis and remission patients exhibited significantly higher OCT-1 mRNA than normal individuals (P<0.05).
BCR-ABL drives myeloid differentiation and hence increases OCT-1 activity
To more clearly investigate the role that BCR-ABL plays in OCT-1 activity, the promyeloblastic HL60 cell line was transduced with lentivirus constitutively expressing a 'wild-type' BCR-ABL 2A-peptide-linked to eGFP (CMV.BCRABL) or control vector (CMV.CV) and then purified by FACS. BCR-ABL expression and signaling was confirmed in the CMV.BCRABL HL60 cell line using quantitative PCR and Western blot for phosphorylated Crkl (pCrkl, Online Supplementary Figure S3) . BCR-ABL expression was found to be expressed at normal levels by comparison with the CML cell line K562. As shown in Figure 4 , no difference in OCT-1 activity or OCT-1 mRNA expression OCT-1 activity, cell lineage and BCR-ABL haematologica | 2011; 96 (2) 217 was observed between the two cell lines. These findings suggest that the presence of BCR-ABL alone has no direct effect on OCT-1 activity or expression.
To induce granulocyte differentiation, vector control and BCR-ABL-transduced HL60 cell lines were cultured in media supplemented with 1.25% DMSO for seven days. As expected, DMSO treatment resulted in changes in cell morphology as evidenced by a more lobular nuclei ( Figure  5A ), a reduction in cell growth ( Figure 5B ), an accumulation in the G0/G1 cell cycle phase ( Figure 5C ) and an increase in CD11b cell surface expression ( Figure 5D ), all consistent with granulocytic differentiation. Notably, CMV.BCRABL HL60 were found to differentiate more than vector control cells as evidenced by increased nuclear segmentation ( Figure 5A ) and increased CD11b expression ( Figure 5D ). Differentiation was associated with increased OCT-1 mRNA expression in both cell lines, although this was not significant ( Figure 5E ). Interestingly, while the OCT-1 activity in the control vector line did not significantly change following DMSO treatment, the OCT-1 activity in HL60 CMV.BCRABL significantly increased from a mean of 5.8 to 18.6 ng/200,000 cells ( Figure 5F , P=0.024).
Therefore, whilst BCR-ABL alone appears not to have an effect on OCT-1 expression or activity, the presence of BCR-ABL clearly plays a role in driving granulocyte differentiation which in turn results in an increase in OCT-1 activity.
Discussion
OCT-1 activity, measured in mononuclear cells at diagnosis, is a strong predictive test to identify patients who will respond well to treatment and, more importantly, to identify patients who are most likely to fail treatment or progress. An understanding of the biology of OCT-1 activity is central to identifying those patients who are likely to be poor responders to imatinib therapy and in developing new strategies to better target these patients at risk.
The present study identified that the mononuclear cell compartment in CML diagnosis patients is comprised predominantly of a mixture of granulocytes at varying stages of differentiation. Notably, purified populations of neutrophils, monocytes and lymphocytes exhibited differences in imatinib uptake, with neutrophils showing the greatest OCT-1 activity and lymphocytes the lowest. A recent study suggested that differences in imatinib uptake between patient cells and cell lines may be associated with cell volume. 32 Given the considerable size differences between neutrophils and lymphocytes it is possible that reduced cell volume may contribute to the lower OCT-1 activity seen in lymphocytes. When MNC OCT-1 activity was correlated with OCT-1 activity in neutrophils, monocytes and lymphocytes, the strongest significant relationship was observed between MNC OCT-1 activity and neutrophil OCT-1 activity. This was found in both chronic myeloid leukemia patients at diagnosis and normal individuals. As a result, individuals with high MNC OCT-1 activity tend to have high OCT-1 activity in their neutrophils but not necessarily in their monocytes or lymphocytes. Therefore, OCT-1 activity in the granulocyte lineage is likely to be a key contributor to MNC OCT-1 activity in chronic myeloid leukemia patients at diagnosis.
Variation in OCT-1 activity may be a result of variation in OCT-1 mRNA expression. Two recent studies have demonstrated that polymorphonuclear cells had a higher OCT-1 mRNA expression compared with mononuclear cells in normal peripheral blood. 21, 22 Studies presented here show that neutrophils express significantly higher levels of OCT-1 mRNA than lymphocytes in normal, CML diagnosis and CML remission peripheral blood and that mRNA expression relates closely to OCT-1 activity. Bazeos et al. 21 subsequently examined OCT-1 mRNA expression in total white blood cells between CML diagnosis, CML remission and normal donors and found that OCT-1 mRNA expression was increased in CML remission and normal individuals compared to CML diagnosis. This was attributed to an inhibitory effect of BCR-ABL on OCT-1 expression. However, it is important to remember that between these groups, the total white blood cell population may be comprised of markedly different cell populations/cell ratios. In normal peripheral blood, total white blood cells consist of approximately 70% neutrophils, which would be similar to what would be observed in chronic myeloid leukemia patients in complete cytogenetic remission. However, as we and others 22 have demonstrated, CML diagnosis peripheral blood contains more immature forms of granulocytes (i.e. myelocytes and metamyelocytes) which are not seen in normal peripheral blood. These differences in the total white blood cell population may be influencing the results of Bazeos et al. 21 To overcome this, we have compared OCT-1 activity and mRNA expression in the mature neutrophil population recovered from CML diagnosis, CML remission and normal donors and have found no significant difference in OCT-1 activity or expression. Furthermore, we found no difference in OCT-1 activity and expression in the HL60 cell line transfected with control vector or BCR-ABL, indicating that BCR-ABL is unlikely to be affecting OCT-1 activity or expression. Of note, there appears to be a trend of increased OCT-1 activity and expression in the neutrophil population recovered from CML remission patients compared to both CML diagnosis and normal individuals. While not reaching statistical significance, possibly due to inadequate numbers, it is tempting to speculate that imatinib itself may have an effect on OCT-1 expression and/or function.
We and others have previously shown that primitive CD34 + cells from chronic myeloid leukemia patients have reduced levels of OCT-1 activity 23 and expression 23, 33 compared to mature CD34-cell indicating a role for cell maturation in OCT-1 regulation. We now substantiate these findings in a cell line model in which we have shown that maturation of the HL60 cell line from a blastic state to a more differentiated granulocyte is associated with an increase in OCT-1 activity and expression. The level of differentiation is enhanced by the presence of BCR-ABL which in turn further increases the OCT-1 activity. This data is in agreement with studies of induced BCR-ABL expression in cord blood CD34 + cells 34 and mouse embryonic stem cells, 35 where BCR-ABL expression induced significant increases in myeloid colonies. While other studies suggest that increased BCR-ABL expression in blast crisis mediates a halt in differentiation, this is usually associated with additional genetic defects such as reduced p5336, and reduced C/EBP-α. 37, 38 Overexpression of BCR-ABL in the pluripotent primitive hematopoietic cell line, FDCP-Mix, resulted in a cell line with characteristics similar to that observed in cells recovered from "chronic phase" chronic myeloid leukemia patients. 39 In this cell line, expression of BCR-ABL along with culture in myeloid differentiation media resulted in preferential granulocyte differentiation. Furthermore, BCR-ABL expression did not induce a block in differentiation as blast cell numbers decreased dramatically. Lastly, a reduction in granulocyte differentiation has been observed in a chronic myeloid leukemia cell line following imatinib treatment 40 .
In conclusion, OCT-1 activity and expression appears to be strongly related to cell lineage and maturity. BCR-ABL does not appear to directly influence OCT-1 activity but may do so by facilitating granulocyte differentiation. Therefore, variation in MNC OCT-1 activity, and hence response to imatinib therapy in chronic myeloid leukemia patients, may be related to factors associated with the majority cell population at diagnosis. 
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